MX2019014848A - Anti-cd38 antibodies and fusions with attenuated alpha-2b interferon. - Google Patents

Anti-cd38 antibodies and fusions with attenuated alpha-2b interferon.

Info

Publication number
MX2019014848A
MX2019014848A MX2019014848A MX2019014848A MX2019014848A MX 2019014848 A MX2019014848 A MX 2019014848A MX 2019014848 A MX2019014848 A MX 2019014848A MX 2019014848 A MX2019014848 A MX 2019014848A MX 2019014848 A MX2019014848 A MX 2019014848A
Authority
MX
Mexico
Prior art keywords
antibodies
interferon
fusions
alpha
well
Prior art date
Application number
MX2019014848A
Other languages
Spanish (es)
Inventor
Clarke Adam
Gerard Doyle Anthony
Pollard Matthew
Behrens Collette
Yamagishi Tetsuo
L Pogue Sarah
Taura Tetsuya
S Jr Wilson David
Original Assignee
Teva Pharmaceuticals Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals Australia Pty Ltd filed Critical Teva Pharmaceuticals Australia Pty Ltd
Priority to MX2019014848A priority Critical patent/MX2019014848A/en
Publication of MX2019014848A publication Critical patent/MX2019014848A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to antibodies specifically binding to CD38, as well as constructs comprising such antibodies fused with attenuated interferon-alpha-2b proteins. Said mixture is useful to inhibit proliferation in cancer cells expressing both CD38 and the IFN-alpha2b receptor, as well as to induce apoptosis in such cells. Also, it serves as the basis for the treatment of underlying cancer.
MX2019014848A 2015-10-28 2015-10-28 Anti-cd38 antibodies and fusions with attenuated alpha-2b interferon. MX2019014848A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2019014848A MX2019014848A (en) 2015-10-28 2015-10-28 Anti-cd38 antibodies and fusions with attenuated alpha-2b interferon.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2019014848A MX2019014848A (en) 2015-10-28 2015-10-28 Anti-cd38 antibodies and fusions with attenuated alpha-2b interferon.

Publications (1)

Publication Number Publication Date
MX2019014848A true MX2019014848A (en) 2020-02-12

Family

ID=72832995

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014848A MX2019014848A (en) 2015-10-28 2015-10-28 Anti-cd38 antibodies and fusions with attenuated alpha-2b interferon.

Country Status (1)

Country Link
MX (1) MX2019014848A (en)

Similar Documents

Publication Publication Date Title
PH12015502439A1 (en) Anti-cd38 antibodies and fusions to attenuated inferferon alpha-2b
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
PH12018501882A1 (en) Binding proteins and methods of use thereof
PH12018501473A1 (en) Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12018500363A1 (en) Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
EA202191380A1 (en) ANTIBODIES TO ALPHA-SYNUCLEINE AND THEIR APPLICATION
UY36154A (en) ANTIBODIES AGAINST THE RECEIVER OF THE TUMOR NECROSIS FACTOR INDICATED BY GLUCOCORTICOIDS (GITR) AND ITS USES
PH12016500943A1 (en) Aplnr modulatros and uses thereof
EA201891709A1 (en) ANTIGENSBINKING PROTEINS, BINDING PD-L1
MX2017003247A (en) Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof.
MX2020014031A (en) Heterodimeric proteins and uses thereof.
PH12019502007A1 (en) Anti-gitr antibodies and methods of use thereof
MX2017014397A (en) Anti-fcrn antibodies.
MY185593A (en) Cortistatin analogues for the treatment of inflammatory and/or immune diseases
MX366178B (en) Human btnl3 proteins, nucleic acids, and antibodies and uses thereof.
EA201690992A1 (en) ANTIBODIES SPECIFIC TO FCRN
GEP20217307B (en) ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MX2016014726A (en) Her1 antigen binding proteins binding to the beta-hairpin of her1.
MX2019014848A (en) Anti-cd38 antibodies and fusions with attenuated alpha-2b interferon.
EA201991027A9 (en) ANTIBODIES AGAINST CD38 AND FUSED PROTEINS WITH A LOWERENED ALPHA-2b INTERFERON
NZ742073A (en) Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
MX2023004302A (en) Anti-cd38 antibodies and fusions with attenuated interferon alfa-2b.
PE20160028A1 (en) ANTI-CD38 ANTIBODIES AND FUSIONS WITH ALPHA-2B ATTENUATED INTERFERON